绞股蓝皂苷XLIX改善糖尿病大鼠肾小球功能的机制研究  

Mechanism of Gypenoside XLIX in improving glomeruli functions of diabetic rats

作　　者：赵璐[1] 孙俊波[2] 魏桂梅[1] 

机构地区：[1]河南中医药大学第三附属医院内分泌科,河南郑州450008 [2]河南省中医院内科,河南郑州450002

出　　处：《现代预防医学》2017年第11期2060-2064,共5页Modern Preventive Medicine

摘　　要：目的研究绞股蓝皂苷XLIX对糖尿病大鼠肾小球功能的影响。方法将Wistar雄性大鼠随机分为8组:正常组、模型组、治疗组(I、II、III)、MK-886组(PPAR-α抑制剂)、模型+MK-886组、治疗+MK-886组,每组10只。大鼠经高糖高脂饲料喂食6周后一次性腹腔注射30mg/kg链脲佐菌素建立糖尿病模型。处理结束后,检测大鼠血糖和血脂水平、24h尿蛋白含量、肾小球滤过率(GFR),检测肾小球组织细胞凋亡及凋亡相关蛋白Bcl2和Bax的表达,同时检测血管细胞粘附分子-1(VCAM-1)的表达。结果与正常组比较,模型组大鼠血糖、总胆固醇、甘油三酯、尿蛋白含量、GFR、肾小球细胞凋亡比例上升而高密度脂蛋白(HDL)含量降低,而绞股蓝皂苷XLIX处理则可下调这些指标并上调HDL-C含量,具有统计学意义(P<0.05)。模型组大鼠肾小球组织中Bcl2蛋白表达下调而Bax蛋白表达上调、VCAM-1表达上升,绞股蓝皂苷XLIX治疗则可逆转这些变化。利用MK-886预处理后,治疗组大鼠VCAM-1表达明显上升。结论绞股蓝皂苷XLIX可降低糖尿病大鼠血糖、血脂水平,改善肾小球功能并通过PPAR-α调控VCAM-1的表达。Objective To investigate the effect of gypenoside XLIX on glomeruli functions diabetic rats. Methods Male Wistar rats were selected and randomized into 8 groups ： normal group, model group, treatment groups （ I, II, III）, MK - 886 （ PPAR - α inhibitor） group, model ＋ MK - 886 group, and treatment ＋ MK - 886 group, with 10 rats in each group. Diabetic rat model was established through treating with high - fat diet for 6 weeks and then intraperitoneally injected with one small dose （ 30 mg/ kg） of streptozotocin （STZ）. At the end of the treatments, the contents of blood sugar, blood fat,24 h urine protein, glomerular filtration rate （GFR） were detected, apoptotic rate and the expression of apoptosis -related proteins like Bcl2 and Bax in glomeruli were analyzed, and the expression of vascular cell adhesion molecules - 1 was evaluated. Results Compared with normal group, the levels of blood sugar, total cholesterol, triglyceride, urine protein, GFR and apoptotic rate were enhanced while high - density lipoprotein （ HDL ） content was reduced in the model group. In contrast, treating with gypenoside XLIX significantly decreased the levels of these indexes and raised HDL content in a dose - dependent way. Furthermore, decreased Bcl2 expression and increased Bax expression in glomeruli as well as increased VCAM - 1 expression in serum and glomeruli were observed in model rats. However, gypenoside XLIX treatment could reverse these effects. Additionally, after the pretreatment of MK- 886 ,VCAM- 1 expression in normal group and model group was unaffected, while that in treatment was augmented. Conclusion Gypenoside XLIX might abate blood sugar levels and blood fat levels,improve glomeruli function, and modulate VCAM - 1 expression via PPARα.

关 键 词：绞股蓝皂苷XLIX 糖尿病大鼠 肾小球 过氧化物酶体增殖物激活受体Α 血管细胞粘附分子-1 

分 类 号：R113[医药卫生—公共卫生与预防医学]